B. Riley Has Pessimistic Outlook of biote FY2025 Earnings

biote Corp. (NASDAQ:BTMD) – Analysts at B. Riley reduced their FY2025 earnings estimates for shares of biote in a research report issued to clients and investors on Thursday, August 7th. B. Riley analyst J. Van. Sinderen now expects that the company will post earnings per share of $0.25 for the year, down from their prior estimate of $0.31. B. Riley has a “Neutral” rating and a $4.00 price objective on the stock. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at $0.02 EPS, FY2026 earnings at $0.29 EPS and FY2027 earnings at $0.42 EPS.

biote (NASDAQ:BTMD) last posted its earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. biote had a net margin of 15.73% and a negative return on equity of 19.71%. The firm had revenue of $48.86 million during the quarter, compared to analyst estimates of $49.52 million.

Separately, Wall Street Zen downgraded biote from a “strong-buy” rating to a “hold” rating in a research report on Saturday.

biote Stock Performance

BTMD stock opened at $2.88 on Monday. The firm has a market cap of $157.56 million, a PE ratio of 3.20 and a beta of 1.21. The firm has a fifty day moving average price of $4.00 and a 200 day moving average price of $4.01. biote has a fifty-two week low of $2.87 and a fifty-two week high of $6.98.

Institutional Trading of biote

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in biote by 7.2% in the second quarter. Geode Capital Management LLC now owns 616,697 shares of the company’s stock valued at $2,480,000 after purchasing an additional 41,333 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in biote in the second quarter valued at approximately $66,000. Los Angeles Capital Management LLC raised its stake in shares of biote by 5.8% during the 2nd quarter. Los Angeles Capital Management LLC now owns 200,345 shares of the company’s stock worth $805,000 after buying an additional 11,040 shares during the period. CWM LLC raised its stake in shares of biote by 952.7% during the 2nd quarter. CWM LLC now owns 8,674 shares of the company’s stock worth $35,000 after buying an additional 7,850 shares during the period. Finally, Strs Ohio purchased a new stake in shares of biote during the first quarter worth approximately $312,000. 21.68% of the stock is currently owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.